Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Lymphocyte adaptor protein LNK deficiency exacerbates hypertension and end-organ inflammation
Mohamed A. Saleh, … , David G. Harrison, Meena S. Madhur
Mohamed A. Saleh, … , David G. Harrison, Meena S. Madhur
Published February 9, 2015
Citation Information: J Clin Invest. 2015;125(3):1189-1202. https://doi.org/10.1172/JCI76327.
View: Text | PDF
Research Article Nephrology

Lymphocyte adaptor protein LNK deficiency exacerbates hypertension and end-organ inflammation

  • Text
  • PDF
Abstract

The lymphocyte adaptor protein LNK (also known as SH2B3) is primarily expressed in hematopoietic and endothelial cells, where it functions as a negative regulator of cytokine signaling and cell proliferation. Single-nucleotide polymorphisms in the gene encoding LNK are associated with autoimmune and cardiovascular disorders; however, it is not known how LNK contributes to hypertension. Here, we determined that loss of LNK exacerbates angiotensin II–induced (Ang II–induced) hypertension and the associated renal and vascular dysfunction. At baseline, kidneys from Lnk–/– mice exhibited greater levels of inflammation, oxidative stress, and glomerular injury compared with WT animals, and these parameters were further exacerbated by Ang II infusion. Aortas from Lnk–/– mice exhibited enhanced inflammation, reduced nitric oxide levels, and impaired endothelial-dependent relaxation. Bone marrow transplantation studies demonstrated that loss of LNK in hematopoietic cells is primarily responsible for the observed renal and vascular inflammation and predisposition to hypertension. Ang II infusion increased IFN-γ–producing CD8+ T cells in the spleen and kidneys of Lnk–/– mice compared with WT mice. Moreover, IFN-γ deficiency resulted in blunted hypertension in response to Ang II infusion. Together, these results suggest that LNK is a potential therapeutic target for hypertension and its associated renal and vascular sequela.

Authors

Mohamed A. Saleh, William G. McMaster, Jing Wu, Allison E. Norlander, Samuel A. Funt, Salim R. Thabet, Annet Kirabo, Liang Xiao, Wei Chen, Hana A. Itani, Danielle Michell, Tianxiao Huan, Yahua Zhang, Satoshi Takaki, Jens Titze, Daniel Levy, David G. Harrison, Meena S. Madhur

×

Figure 6

BMT studies to determine the relative role of hematopoietic versus somatic LNK in the aggravated hypertensive response to Ang II.

Options: View larger image (or click on image) Download as PowerPoint
BMT studies to determine the relative role of hematopoietic versus somat...
(A) Experimental design: BMT was performed using Lnk–/– (CD45.2) and WT SJL (CD45.1) mice as either donors or recipients as indicated. Four groups were designated: SJL/SJL and Lnk–/–/Lnk–/– as 2 control groups and SJL/Lnk–/– and Lnk–/–/SJL as 2 chimeric groups. (B) Telemetry recordings of systolic BP at baseline and during 28 days of a normally subpressor infusion of Ang II (140 ng/kg/min). (C) Percentage of chimerism was assessed by flow cytometry for CD45.1/CD45.2 in peripheral blood mononuclear cells. A representative plot from each group is shown. In all cases, the amount of chimerism was 90% or more. Quantification of flow cytometry for total T lymphocytes (CD45+CD3+ cells) in kidneys (D) and thoracic aortas (E) in the designated 4 groups. (F) 24-hour urinary excretion of albumin in the designated 4 groups. Data are expressed as mean ± SEM (n = 5 per group except for panel E, in which n = 3 per group). For B, repeated measures ANOVA was performed. **P < 0.01 vs. SJL/SJL; ****P < 0.0001 vs. SJL/Lnk–/–. For D–F, 1-way ANOVA was performed. *P < 0.05; **P < 0.01; ****P < 0.0001 vs. SJL/SJL.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts